An open-label, phase II basket study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

ABSTRACT: Purpose: To evaluate whether administration of the oral DNA hypomethylating agent (HMA) CC-486 enhances the poor response rate of immunologically ‘cold’ solid tumors to immune checkpoint inhibitor durvalumab.

ORGANISM(S): Homo sapiens

PROVIDER: GSE147537 | GEO | 2020/07/26

REPOSITORIES: GEO